Clinical trial · Interventional
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
NCT07033026CI-TRIAL-00107071recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Cachexia | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| CRC (Colorectal Cancer) | Colorectal Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NGM120 Q4W | Drug | — | UNRESOLVED |
| NGM120 Q8W | Drug | — | UNRESOLVED |
| Placebo given | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- NGM120 Treatment Group A
- description
- NGM120 low dose given subcutaneously every 4 weeks
- interventionNames
- Drug: NGM120 Q4W
- type
- PLACEBO_COMPARATOR
- label
- NGM120 Treatment Group B
- description
- Placebo low dose given subcutaneously every 4 weeks
- interventionNames
- Drug: Placebo given
- type
- EXPERIMENTAL
- label
- NGM120 Treatment Group C
- description
- NGM120 high dose given subcutaneously every 4 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Documented active diagnosis of colorectal cancer. 2. Cachexia defined by Fearon criteria of weight loss. 3. Signed informed consent. Exclusion Criteria: 1. Current active reversible causes of decreased food intake. 2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization. 3. Have cachexia caused by other reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.